Meta Analysis

Risk factors for methicillin-resistant Staphylococcus aureus colonization and infection in patients with human immunodeficiency virus infection: A systematic review and meta-analysis

Xuefei Hu¹, Keao Hu², Yanling Liu¹, Lingbing Zeng¹, Niya Hu¹, Xiaowen Chen¹ and Wei Zhang³

Abstract

Objective: To investigate the potential factors affecting methicillin-resistant Staphylococcus aureus (MRSA) colonization and infection in patients with human immunodeficiency virus (HIV) infection.

Methods: A systematic search of publications listed in electronic from inception up to August 2020 was conducted. A random-effects model was used to calculate odds ratio (OR) with 95% confidence interval (CI).

Results: A total of 31 studies reporting 1410 MRSA events in 17,427 patients with HIV infection were included. Previous hospitalization (OR 1.80; 95% CI 1.37, 2.36), previous antibiotic therapy (OR 2.69; 95% CI 2.09, 3.45), CD4⁺ count (OR 1.79; 95% CI 1.41, 2.28), Centers for Disease Control and Prevention classification of stage C (OR 2.66; 95% CI 1.80, 3.93), skin lesions (OR 2.02; 95% CI 1.15, 3.55), intravenous device use (OR 2.61; 95% CI 1.59, 4.29) and an MRSA

¹Clinical Laboratory of the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China
²Department of Urology, The First Clinical College of Nanchang University Medical College, Nanchang, Jiangxi Province, China
³Department of Respiration, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China

Corresponding author: Wei Zhang, Department of Respiration, The First Affiliated Hospital of Nanchang University, 17 Yongwai Zhongjie, Donghu District, Nanchang City, 330006, Jiangxi Province, China.
Email: Zhangweiliuxin@163.com
colonization history (OR 6.30; 95% CI 2.50, 15.90) were significantly associated with an increased risk of MRSA colonization and infection. Antiretroviral therapy (OR 0.71; 95% CI 0.50, 0.99) and current antibiotic use (OR 0.13; 95% CI 0.05, 0.32) were significantly associated with a reduced risk of MRSA colonization and infection. **Conclusion:** MRSA colonization and infection in HIV-infected patients is associated with a number of risk factors.

**Keywords**
Methicillin-resistant Staphylococcus aureus, human immunodeficiency virus, skin and soft-tissue infections, comprehensive risk stratification

Date received: 24 April 2021; accepted: 10 November 2021

**Introduction**
The prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) infection has been increasing globally. The infection-causing staphylococci could be a harmless commensal or a potentially life-threatening pathogen.1,2 MRSA infections range from localized skin and soft-tissue infections to disseminated blood stream infections, which result in substantial healthcare costs, morbidity and mortality.3–5 At present, the association of MRSA colonization with human immunodeficiency virus (HIV) infection is of particular interest because of the association of morbidity and mortality with MRSA in patients with HIV infection.6 The potential reasons for this are that bacterial infections have been considered the most prevalent events affecting patients with HIV infection and that MRSA possesses important virulence factors and frequently acquires resistance to various antibiotics.7 Although several studies have illustrated MRSA prevalence and severity in patients with HIV infection, the factors predisposing such patients to MRSA colonization and infection have not been illustrated well.7–13

A previous systematic review explored the potential factors associated with MRSA at the time of admission to hospital or an intensive care unit.14 It included 29 studies and identified that the potential risk factors included previous hospitalization, nursing home exposure, the history of exposure to healthcare-associated pathogens, congestive heart failure, diabetes mellitus, pulmonary disease, immunosuppression and renal failure.14 A previous systematic review of nine studies with high methodological quality (level A) indicated that antimicrobial use and previous hospitalization were independent risk factors for MRSA colonization in patients with HIV infection.15 However, these systematic reviews were not restricted to patients with HIV infection and did not perform quantitative analysis.14,15 Identifying the potential risk factors for MRSA colonization and infection is particularly important in patients with HIV infection; however, these risk factors remain to be definitively determined. Therefore, a systematic review and meta-analysis was performed to explore the potential risk factors for MRSA colonization and infection in patients with HIV infection.
Materials and methods

Data sources and search strategy

A systematic search of publications listed in electronic databases (PubMed®, EMBASE and the Cochrane Library) from inception up to August 2020 was conducted using the following key words or Medical Subject Heading terms: (“human immunodeficiency virus” OR “immunodeficiency” OR “immunocompromised” OR “HIV” OR “AIDS”) AND (“Staphylococcus” OR “Staphylococcus aureus” OR “methicillin-resistant Staphylococcus aureus” OR “MRSA” OR “resistant bacterial infection”) AND “human”. Studies reporting the risk factors for MRSA colonization and infection in patients with HIV infection were included in this analysis. There were no restrictions based on language or status. Corresponding authors were contacted to obtain additional data if the reported data were insufficient. A manual review of references from the selected articles was undertaken to identify any other eligible studies. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement (PRISMA; 2009) guidelines were followed to perform and report this systematic review and meta-analysis.16

Selection criteria

A study was included if it met all of the following inclusion criteria: (i) Patients: patients with HIV infection; (ii) Exposure: the identified factors were reported in ≥3 studies; (iii) Outcome: MRSA colonization and infection, reported effect estimates, or the reported data could be translated into odds ratio (OR) and 95% confidence interval (CI); and (iv) Study design: cross-sectional, case-control and cohort studies. Studies designed as case reports, case series or reviews, and those involving animal models, were excluded. Two reviewers (X.H. & W.Z.) independently screened the eligible studies based on the title, abstract and full text of each study. Any inconsistency in the data obtained by the two reviewers was settled by a third reviewer (K.H.) by reading the full text of the article.

Data collection and quality assessment

The data from the retrieved studies were independently extracted by two reviewers (Y.L. & L.Z.) in a standard data abstraction form. Any disagreement was resolved by discussion until a consensus was reached. Data on the selected variables collected from each study included the following: the first author's surname, publication year, country, study design, sample size, MRSA colonization and infection events, mean age, male proportion, sample type, dominant strain, adjusted factors and reported outcomes.

The methodological quality of each individual study was assessed by using the Newcastle–Ottawa Scale (NOS), which is a comprehensive and partially validated scale for assessing the quality of observational studies.17 The starring system of NOS is based on selection (4 items), comparability (1 item) and outcome (3 items); and ‘star system’ ranges from 0 to 9 stars.17 The quality assessment was independently performed by two reviewers (X.H. & W.Z.) and any conflicts between the reviewers were settled by an additional reviewer (N. H.) by reading the full text of the retrieved articles.

Statistical analyses

All analyses were performed using Stata® software (version 10.0; Stata Corporation, College Station, TX, USA). The effect estimates regarding the risk factors for MRSA colonization and infection were assigned as OR and 95% CI for each study and the pooled analyses were performed using
a random-effects model. The heterogeneity across the included studies was assessed using the $I^2$ and Q statistic; and significant heterogeneity was defined as $I^2 > 50\%$ or $P_{Q\text{ statistic}} < 0.10$. The stability of pooled conclusions for factors reported in $\geq 10$ studies was assessed using sensitivity analysis through the sequential exclusion of individual studies. Subgroup analyses for these factors were evaluated based on country, study design and reported outcomes, and the differences among the subgroups were assessed using the interaction $P$-test, which assumes that the data distribution met the $t$-test criteria. Publication bias for the factors reported in $\geq 10$ studies were assessed using the funnel plot, Egger’s test and Begg’s test. The $P$-value for pooled results was two-sided and the inspection level was 0.05.

**Results**

In total, 5743 articles were identified from the initial electronic database searches and 3143 were retained after the removal of duplicate articles. A further 2971 articles were excluded because of irrelevant titles or abstracts and the remaining 172 were used for further full-text evaluations. Of these articles, 141 were further excluded because of unreported risk factors ($n = 63$), factors in $< 3$ studies ($n = 52$), unreported MRSA events ($n = 17$) or review or meta-analysis ($n = 9$). Reviewing the reference lists of the remaining studies did not yield any new eligible studies as all relevant studies had already been included during the database searches. A total of 31 studies, representing a total of 17 427 patients with HIV infection, were selected for the final meta-analysis. The details of the literature search and study selection are summarized in a PRISMA flow diagram (Figure 1).

The baseline characteristics of the included studies and recruited patients are presented in Table 1. Of the 31 included studies, eight had a cohort design, 17 had a cross-sectional design and the remaining six studies had a case–control design. These studies reported a total of 1410 MRSA colonization events and the events of MRSA colonization and infection that occurred in each study ranged from 6 to 252. Of the studies, five were conducted in Europe, 15 in North or South America, five in Africa and the remaining six in Asia. In total, 20 studies reported the crude data and the remaining 11 reported adjusted effect estimates. The quality of the included studies was assessed using the NOS, which rated 5 stars to 17 studies and 4 stars to the remaining 14 studies (Table 2).

A total of 18 studies reported sex difference as a risk factor for MRSA colonization and infection in patients with HIV infection. No significant difference was noted between males and females regarding the risk of MRSA colonization and infection in patients with HIV infection ($OR = 0.91; 95\% CI 0.77, 1.07; P = 0.247$; Figure 2) and nonsignificant heterogeneity across the included studies was detected ($I^2 = 10.8\% ; P = 0.326$). When the study conducted by Popovich 2013 was excluded, sensitivity analysis suggested men with HIV infection had a lower risk of MRSA colonization and infection than females with HIV infection (Figure 3A). The results of pooled analyses in all subgroups were consistent with those of the overall analysis and only nonsignificant differences between males and females remained (Table 3). No significant publication bias for sex difference as a risk factor for MRSA colonization and infection was detected ($P$-value for Egger’s test, 0.665; $P$-value for Begg’s test, 0.880; Figure 4A).

In total, 14 studies reported previous hospitalization as a risk factor for MRSA colonization and infection in patients with HIV infection.
Previous hospitalization was associated with an increased risk of MRSA colonization and infection (OR 1.80; 95% CI 1.37, 2.36; \( P < 0.001 \); Figure 5) and significant heterogeneity was found across the included studies (\( \hat{I}^2 = 68.3\% ; \ P < 0.001 \)). This conclusion was robust and not altered by the sequential exclusion of individual studies (Figure 3B). Although the results of subgroup analyses were consistent with those of the overall analysis in most subgroups, previous hospitalization was not associated with the risk of MRSA colonization and infection for pooled studies conducted in Asia (Table 3). Although Begg’s test results revealed no significant publication bias for previous hospitalization (\( P = 0.324 \)), Egger’s test results showed potential significant publication bias for previous hospitalization as a risk factor for MRSA colonization and infection (\( P = 0.008 \); Figure 4B). This conclusion was not altered after adjusting for the potential publication bias using the trim-and-fill method.\(^57\)

A total of 16 studies reported previous antibiotic therapy as a risk factor for MRSA colonization and infection in patients with HIV infection.\(^{27–29,32,35–38,40,43,47,50–53,56}\)
Table 1. Major characteristics of the 31 studies selected for the meta-analysis to identify potential risk factors for methicillin-resistant *Staphylococcus aureus* (MRSA) colonization and infection in patients with human immunodeficiency virus infection (HIV). 26–56

| Study          | Country | Study design | Sample size | Positive sample | Mean age, years | Male, % | Type of sample | Dominant MRSA strain | Adjusted factors                                                        |
|----------------|---------|--------------|-------------|-----------------|----------------|---------|----------------|----------------------|----------------------------------------------------------------------|
| Sissolak 2002  | Austria | Cross-sectional | 47          | 20              | 40.2           | 85.1    | Nares          | NA                   | Crude                                                              |
| Tumbarello 2002 | Italy   | Cohort       | 129         | 41              | 34.6           | 65.9    | Blood          | NA                   | Crude                                                              |
| McDonald 2003  | China   | Cohort       | 162         | 9               | 35.0           | 92.0    | Nares          | NA                   | Crude                                                              |
| Villacian 2004  | Singapore | Cross-sectional | 195       | 6               | NA             | NA      | Nares          | NA                   | Crude                                                              |
| Mathews 2005   | USA     | Cohort       | 3455        | 126             | 39.0           | 86.0    | All            | NA                   | Race or ethnicity and HIV transmission risk factors                |
| Drapeau 2007   | Italy   | Case–control | 5257        | 28              | 43.0           | 74.0    | Wound, blood, respiratory and skin | NA                   | Age at enrolment                                                     |
| Cenizal 2008   | USA     | Cross-sectional | 146         | 15              | 42.0           | 83.6    | Nares, axilla  | USA300/SCC-mec type IV | Crude                                                              |
| Padoveze 2008  | Brazil  | Cohort       | 111         | 69              | 36.9           | 62.2    | Nares          | NA                   | Crude                                                              |
| Cotton 2008    | South Africa | Cross-sectional | 203       | 34              | 1.3           | 52.7    | Nasopharynx    | NA                   | Age, stage, sex, immunological and weight for age-Z-score           |
| Shet 2009      | USA     | Case–control | 107         | 18              | 37.5           | NA      | Nares, axilla  | USA300/SCC-mec type IV | Crude                                                              |
| Ramsetty 2010  | USA     | Cohort       | 219         | 72              | 43.0           | 63.5    | Nares          | USA300               | Crude                                                              |
| Giuliani 2010  | Italy   | Cross-sectional | 104         | 24              | 38.3           | 100.0   | Nares          | USA300               | Crude                                                              |
| Crum-Cianflone 2011 | USA | Cross-sectional | 550         | 22              | 42.0           | 93.3    | Nares, axilla, groin, perianal, prerectal and thorax | USA300/ SCC-mec-type IV | Age, ethnicity and clinical site                                   |
| Siberry 2012   | USA     | Cross-sectional | 1813        | 14              | 18.0           | 45.0    | Nares          | NA                   | Crude                                                              |
| Kyaw 2012      | Singapore | Case–control | 296         | 15              | 43.4           | 86.8    | Nares, axilla, groin, perineum, prerectal, thora and wound | NA                   | Lymphoma, CD4, household member, hospitalized, presence of percutaneous device, pneumonia and age |
| Popovich 2013  | USA     | Cross-sectional | 374         | 76              | 44.4           | 75.0    | Nares, axilla, groin, perineum, prerectal, thorax and wound | USA300               | Sex, race, ethnicity, incarceration exposure, temporary housing, illicit drug use, age and residence in a nursing home or long-term care facility in the past year |
| Study            | Country          | Study design | Sample size | Positive sample | Mean age, years | Male, % | Type of sample | Dominant MRSA strain | Adjusted factors                                                                 |
|------------------|------------------|--------------|-------------|-----------------|-----------------|---------|----------------|----------------------|--------------------------------------------------------------------------------|
| Oliva 2013       | Italy            | Cohort       | 63          | 16              | 46.7            | 61.9    | Nares          | NA                   | Crude                                                               |
| Everett 2014     | USA              | Case-control | 46          | 26              | 46.0            | 76.0    | Nares          | NA                   | Crude                                                               |
| Vyas 2014        | USA              | Cohort       | 794         | 63              | 30.0            | 93.8    | Nares          | NA                   | Crude                                                               |
| Farley 2015      | USA              | Cross-sectional | 500      | 77              | NA              | 66.0    | Nares          | NA                   | Sexual orientation, race, CD4 count, prophylaxis, number of sex partners, hands-on job and education |
| Lemma 2015       | Ethiopia         | Cross-sectional | 400      | 24              | 10.0            | 56.0    | Nares          | NA                   | Crude                                                               |
| Gebremedhin 2016 | Ethiopia         | Cross-sectional | 249      | 6               | 35.0            | 30.1    | Nares and thorax | NA                   | Crude                                                               |
| Vieira 2016      | Brazil           | Case-control | 117         | 32              | 12.5            | 41.0    | Nares          | Spa types t002/ST5 and t318/ST30 | Crude                                                               |
| Olalekan 2016    | Nigeria          | Cross-sectional | 187      | 51              | 40.7            | 19.8    | Nares          | NA                   | Age, sex                                                           |
| Farley 2017      | USA              | Cross-sectional | 77        | 28              | 50.7            | 49.4    | Nares, perineum and wound | NA                   | Crude                                                               |
| Alexander 2017   | India            | Cohort       | 194         | 49              | 43.0            | 55.7    | Nares          | NA                   | Crude                                                               |
| Reid 2017        | Botswana         | Cross-sectional | 404      | 252             | 43.0            | 27.2    | Nares          | NA                   | Crude                                                               |
| Regina Pedrosa Soares 2018 | Brazil | Cross-sectional | 157      | 22              | 41.5            | 67.5    | Nares          | SCC-mec-type V | Crude                                                               |
| Hirota 2020      | Japan            | Case-control | 132         | 76              | 39.6            | 97.7    | Nares          | NA                   | Age, MSM, CD4+ cell count, plasma HIV-1 RNA level, use of integrase inhibitors, history of acquired immunodeficiency syndrome, time of SSTI onset and SSTI sites |
| Popovich 2020    | USA              | Cross-sectional | 386      | 80              | 37.6            | 100.0   | Nares, throat and bilateral inguinal area | USA300         | Race/ethnicity, injection drug use in the past year, receives HIV care at clinic and current skin infection |
| Hsu 2020         | China            | Cross-sectional | 553      | 19              | 41.2            | 96.0    | Nares          | SCC-mec-types IIIA, IV and VT | Sex, injection drug user, male-to-male sex, smoking, HCV carrier, cancer and antibiotic use within the past 1 year |

NA, not available; SCC, staphylococcal chromosome cassette; MSM, men having sex with men; SSTI, skin and soft-tissue infection; HCV, hepatitis C virus.
Table 2. The Newcastle–Ottawa Scale (NOS) rating for the individual studies included in the meta-analysis to identify potential risk factors for methicillin-resistant *Staphylococcus aureus* colonization and infection in patients with human immunodeficiency virus infection.26–56

| Study               | Selection | Outcome | Study               | Selection | Outcome |
|---------------------|-----------|---------|---------------------|-----------|---------|
| Sissolak 2002       | —         | *       | Tumbarello 2002     | —         | *       |
| McDonald 2003       | —         | *       | Villacian 2004      | —         | *       |
| Mathews 2005        | *         | —       | Drapeau 2007       | —         | *       |
| Cotton 2008         | —         | *       | Cenizal 2008        | —         | *       |
| Shet 2009           | —         | *       | Ramsetty 2010       | —         | *       |
| Giuliani 2010       | —         | *       | Crum-Cianflone 2011 | —         | *       |
| Siberry 2012        | —         | *       | Kyaw 2012           | —         | *       |
| Popovich 2013       | —         | *       | Oliva 2013          | —         | *       |
| Everett 2014        | —         | *       | Vyas 2014           | —         | *       |
| Vyas 2014           | —         | *       | Farley 2015         | —         | *       |
| Lemma 2015          | —         | *       | Lebedford 2016      | —         | *       |
| Vieira 2016         | —         | *       | Vieira 2016         | —         | *       |
| Olalekan 2016       | —         | *       | Farley 2015         | —         | *       |
| Farley 2017         | —         | *       | (continued)         | —         | *       |
The pooled result indicated that previous antibiotic therapy was associated with an increased risk of MRSA colonization and infection (OR 2.69; 95% CI 2.09, 3.45; \( P < 0.001 \); Figure 6) and nonsignificant heterogeneity was detected among included studies (\( I^2 = 19.5\% \); \( P = 0.231 \)). Sensitivity analysis indicated the pooled conclusion was stable after excluding any particular study (Figure 3C). Subgroup analyses revealed the negative effect of previous antibiotic therapy on the risk of MRSA colonization and infection in most subgroups; however, previous antibiotic therapy was not associated with this risk when pooled with the results obtained from a study conducted in Europe (Table 3). No significant publication bias for previous antibiotic therapy as a risk factor for MRSA colonization and infection was detected (\( P \)-value for Egger’s test, 0.417; \( P \)-value for Begg’s test, 0.192; Figure 4C).

In total, 15 studies reported the CD4\( ^+ \) count for the risk of MRSA colonization and infection in patients with HIV infection. A low CD4\( ^+ \) count was associated with an increased risk of MRSA colonization and infection (OR 1.79; 95% CI 1.41, 2.28; \( P < 0.001 \); Figure 7) and a potential significant heterogeneity was detected across the included studies (\( I^2 = 39.7\% \); \( P = 0.057 \)). The results of sensitivity analysis showed that the pooled conclusion did not change after the sequential exclusion of any individual study (Figure 3D). Subgroup analyses showed that low CD4\( ^+ \) count was not associated with an MRSA colonization and infection risk when pooled with studies conducted in Asia or studies with a case-control design (Table 3). Although Begg’s test results indicated no significant publication bias (\( P = 0.843 \)), Egger’s test results revealed a potential publication bias for CD4\( ^+ \) count as a risk factor for MRSA colonization and infection (\( P = 0.043 \)) (Figure 4D). The pooled conclusion
remained unaltered after adjusting for publication bias using the trim-and-fill method.\textsuperscript{57}

Eight and seven studies reported that highly active antiretroviral therapy (HAART) and antiretroviral therapy (ART), respectively, were associated with an MRSA colonization and infection risk (Figure 8).\textsuperscript{26,28–33,35,37–39,44,45,53} ART was associated with a reduced risk of MRSA colonization and infection (OR 0.71; 95% CI 0.50, 0.99; $P = 0.041$), whereas HAART was not associated with this risk (OR 0.86; 95% CI 0.57, 1.32; $P = 0.495$). A significant heterogeneity was detected for ART ($I^2 = 49.6\%; P = 0.064$), but nonsignificant heterogeneity was detected for HAART ($I^2 = 20.1\%; P = 0.270$).

Six and seven studies reported the association of Centers for Disease Control and Prevention (CDC) classification and viral load, respectively, with the risk of MRSA colonization and infection (Figure 9).\textsuperscript{26,27,30–32,34,37,44,48,49,53,54} The CDC classification of stage C was associated with an increased risk of MRSA colonization and infection (OR 2.66; 95% CI 1.80, 3.93; $P < 0.001$), whereas the viral load was not associated with this risk (OR 1.64; 95% CI 0.95, 2.83; $P = 0.075$). No heterogeneity was detected for CDC classification of stage C ($I^2 = 0.0\%; P = 0.516$), whereas significant heterogeneity was detected for viral load ($I^2 = 61.1\%; P = 0.017$).

The number of studies that reported the association of current antibiotic use, skin lesions, intravenous device use, current trimethoprim–sulfamethoxazole (TMP–SMX) use, and an MRSA colonization history with the risk of MRSA colonization and infection was three, four, four, eight, and

**Figure 2.** Association of sex difference with the risk of methicillin-resistant Staphylococcus aureus colonization in patients with human immunodeficiency virus infection. OR, odds ratio; CI, confidence interval.\textsuperscript{27,32,34,36,38–42,44–49,52,53,56}
Skin lesions (OR 2.02; 95% CI 1.15, 3.55; \(P = 0.015\)), intravenous device use (OR 2.61; 95% CI 1.59, 4.29; \(P < 0.001\)) and an MRSA colonization history (OR 6.30; 95% CI 2.50, 15.90; \(P < 0.001\)) were associated with an increased risk of MRSA colonization and infection, whereas the current use of antibiotics was associated with a reduced risk of MRSA colonization and infection (OR 0.13; 95% CI 0.05, 0.32; \(P < 0.001\)). The current use of TMP–SMX was not associated with an MRSA colonization and infection risk (OR 1.48; 95% CI 0.81, 2.69; \(P = 0.203\)). Significant heterogeneity was detected for an MRSA colonization history (\(I^2 = 72.9\%\); \(P = 0.002\)), but not for current antibiotic use (\(I^2 = 0.0\%\); \(P = 0.399\)), skin lesions (\(I^2 = 0.0\%\); \(P = 0.706\)), intravenous device use (\(I^2 = 0.0\%\); \(P = 0.553\)) and current TMP–SMX use (\(I^2 = 39.7\%\); \(P = 0.114\)), across the included studies.

**Discussion**

From 31 studies, the present meta-analysis analysed data from a total of 1410 MRSA events in 17 427 patients with HIV infection. The current findings suggest that previous hospitalization, previous antibiotic therapy, CD4+ count, CDC classification stage C of HIV, skin lesions, intravenous device use and an MRSA colonization history increase the risk of MRSA colonization and infection, whereas ART and the
Table 3. Subgroup analyses based on country, study design and reported outcomes for the meta-analysis to identify potential risk factors for methicillin-resistant *Staphylococcus aureus* (MRSA) colonization and infection in patients with human immunodeficiency virus infection.26–56

| Outcomes                              | Factors                      | Groups                | Number of studies | OR (95% CI)         | P-value | I² (%) | P< subgroups | P-value between subgroups |
|----------------------------------------|------------------------------|-----------------------|--------------------|---------------------|---------|--------|--------------|--------------------------|
| Male versus female                     | Country                      | European region       | 2                  | 0.83 (0.47, 1.46)   | P = 0.515 | 0.0     | 0.609        | P = 0.865                |
|                                        | Region of Americas           | 9                     | 0.92 (0.67, 1.26)  | P = 0.603           |          | 43.5   | 0.078        |                          |
|                                        | African region               | 5                     | 0.89 (0.70, 1.12)  | P = 0.305           |          | 0.0    | 0.778        |                          |
|                                        | Asian region                 | 2                     | 0.75 (0.12, 4.54)  | P = 0.750           |          | 52.7   | 0.146        |                          |
| Study design                           | Cohort                       | 4                     | 0.90 (0.64, 1.28)  | P = 0.570           |          | 0.0    | 0.432        | P = 0.520                |
|                                        | Cross-sectional              | 13                    | 0.92 (0.75, 1.13)  | P = 0.440           |          | 20.0   | 0.242        |                          |
|                                        | Case–control                 | 1                     | 0.56 (0.24, 1.32)  | P = 0.184           |          | –      | –            |                          |
| Report outcomes                        | MRSA colonization            | 14                    | 0.90 (0.74, 1.09)  | P = 0.267           |          | 20.3   | 0.232        | P = 0.930                |
|                                        | MRSA infection               | 4                     | 0.93 (0.57, 1.51)  | P = 0.774           |          | 0.0    | 0.437        |                          |
| Previous hospital admission            | Country                      | European region       | 1                  | 1.11 (1.01, 1.21)   | P = 0.022 | –      | –            | P < 0.001                |
|                                        | Region of Americas           | 7                     | 2.16 (1.37, 3.40)  | P = 0.001           |          | 51.4   | 0.055        |                          |
|                                        | African region               | 4                     | 1.42 (1.10, 1.84)  | P = 0.008           |          | 0.0    | 0.487        |                          |
|                                        | Asian region                 | 2                     | 3.27 (0.84, 12.78) | P = 0.089           |          | 57.4   | 0.125        |                          |
| Study design                           | Cohort                       | 2                     | 2.89 (1.42, 5.87)  | P = 0.003           |          | 57.2   | 0.126        | P < 0.001                |
|                                        | Cross-sectional              | 9                     | 1.69 (1.33, 2.15)  | P < 0.001           |          | 21.0   | 0.256        |                          |
|                                        | Case–control                 | 3                     | 1.11 (1.01, 1.21)  | P = 0.023           |          | 0.0    | 0.687        |                          |
| Report outcomes                        | MRSA colonization            | 13                    | 1.97 (1.49, 2.59)  | P < 0.001           |          | 40.9   | 0.062        | P < 0.001                |
|                                        | MRSA infection               | 1                     | 1.11 (1.01, 1.21)  | P = 0.022           |          | –      | –            |                          |
| Previous antibiotic therapy            | Country                      | European region       | 2                  | 1.83 (0.64, 5.22)   | P = 0.257 | 70.8   | 0.064        | P = 0.105                |
|                                        | Region of Americas           | 7                     | 2.61 (1.82, 3.74)  | P < 0.001           |          | 20.9   | 0.270        |                          |
|                                        | African region               | 2                     | 1.88 (1.09, 3.25)  | P = 0.024           |          | 0.0    | 0.629        |                          |
|                                        | Asian region                 | 5                     | 4.56 (2.71, 7.67)  | P < 0.001           |          | 0.0    | 0.866        |                          |
| Study design                           | Cohort                       | 4                     | 3.60 (2.53, 5.13)  | P < 0.001           |          | 0.0    | 0.708        | P = 0.093                |
|                                        | Cross-sectional              | 10                    | 2.24 (1.56, 3.23)  | P < 0.001           |          | 25.6   | 0.208        |                          |
|                                        | Case–control                 | 2                     | 2.72 (1.40, 5.27)  | P = 0.003           |          | 0.0    | 0.518        |                          |
| Report outcomes                        | MRSA colonization            | 14                    | 2.63 (1.94, 3.55)  | P < 0.001           |          | 28.7   | 0.149        | P = 0.586                |
|                                        | MRSA infection               | 2                     | 3.02 (1.86, 4.90)  | P < 0.001           |          | 0.0    | 0.745        |                          |
| Country                                | European region              | 2                     | 2.75 (1.14, 6.60)  | P = 0.024           |          | 14.0   | 0.281        | P = 0.260                |

(continued)
current use of antibiotics reduce the risk of MRSA colonization and infection. The association between previous hospitalization and MRSA colonization and infection risk varied when stratified by country, study design, and reported outcomes, whereas that between CD4+ count and MRSA colonization and infection risk varied when stratified by study design and reported outcomes.

A previous systematic review performed reported that the overall prevalence of MRSA colonization was 6.9% in patients with HIV infection.58 Previous hospitalization within 12 months and previous or current incarceration were associated with an increased risk of MRSA colonization, whereas current ART and TMP–SMX use were not associated with this risk.58 A previous study reported that the prevalence of MRSA in patients with HIV infection was 7%, with the highest prevalence observed in Southeast Asia (16%), second highest in the Americas (10%) and the lowest in Europe (1%).59 Moreover, they reported that previous MRSA infection, hospitalization in the previous year and antibiotic use increased the risk of MRSA colonization in these patients.59 However, these two previous studies did not address whether the pooled results vary based on country, study design and reported outcomes.58,59 Therefore, the present study aimed to identify the comprehensive risk factors for MRSA colonization and infection in patients with HIV infection.

This current meta-analysis identified several risk factors for MRSA colonization and infection in HIV-infected patients, including previous hospitalization, previous antibiotic therapy, CD4+ count, CDC classification of stage C, skin lesions, intravenous device use and an MRSA colonization history. Several reasons could explain these results. First, previous hospitalization could increase interactions with other potentially infected patients as well as healthcare staff.

| Factors          | OR (95% CI)       | P-value | I2 (%) | P_Q statistic | P-value between subgroups |
|------------------|-------------------|---------|--------|---------------|---------------------------|
| CD4⁺ count       |                   |         |        |               |                           |
| (low versus high)| 1.73 (1.26, 2.37) | 0.001   | 46.9   | 0.058         |                           |
|                  | 1.57 (1.02, 2.41) | 0.040   | 0.0    | 0.906         |                           |
|                  | 2.30 (0.69, 7.64) | 0.174   | 66.5   | 0.084         |                           |
|                  | 1.48 (1.24, 1.77) | 0.001   | 0.0    | 0.457         |                           |
|                  | 1.39 (1.26, 1.53) | 0.001   | 0.0    | 0.372         |                           |
|                  | 3.05 (2.03, 4.60) | 0.001   | 0.0    | 0.16          |                           |
|                  |                   |         |        |               |                           |
| Study design     |                   |         |        |               |                           |
| Cohort           | 1.48 (1.24, 1.77) | 0.001   | 0.0    | 0.539         |                           |
| Cross-sectional  | 1.69 (1.48, 2.03) | 0.001   | 0.0    | 0.887         |                           |
|                  |                   |         |        |               |                           |
| Report outcomes  |                   |         |        |               |                           |
| MRSA colonization| 2.30 (0.69, 7.64) | 0.174   | 66.5   | 0.084         |                           |
| MRSA infection   | 3.05 (2.03, 4.60) | 0.001   | 0.0    | 0.16          |                           |
and contact with materials contaminated with MRSA. Secondly, a higher frequency of antibiotic exposure could accelerate the progression of antimicrobial resistance.50,61 Thirdly, CD4+ count reflects the severity of immunodeficiency, which could increase the susceptibility to MRSA colonization and infection. Fourthly, CDC classification of stage C was significantly associated with the severity of infection in these patients; the susceptibility to MRSA colonization and infection was stronger in patients with a CDC classification of stage C than those with a CDC classification of stage A or B. Fifthly, skin lesions are significantly associated with infection and antibiotic exposure. Sixthly, the use of intravenous devices could increase the risk of MRSA colonization.62 Finally, a previous MRSA colonization history was associated with persistent colonization in nares or other body sites.63,64

This current meta-analysis found that ART and current antibiotic use were associated with a reduced risk of MRSA colonization and infection. The potential reason for this is likely associated with the reduced

Figure 4. Funnel plots: (a) funnel plot for the role of sex difference on the risk of methicillin-resistant Staphylococcus aureus (MRSA) colonization in human immunodeficiency virus infection (HIV)-infected patients; (b) funnel plot for the role of previous hospital admission on the risk of MRSA colonization in HIV-infected patients; (c) funnel plot for the role of previous antibiotic therapy on the risk of MRSA colonization in HIV-infected patients; (d) funnel plot for the role of CD4+ count on the risk of MRSA colonization in HIV-infected patients.
Figure 5. Association of previous hospitalization with the risk of methicillin-resistant *Staphylococcus aureus* colonization in patients with human immunodeficiency virus infection. OR, odds ratio; CI, confidence interval.29,31,32,34–36,38,45–48,50–52

| Study                | OR (95% CI) | Weight |
|----------------------|-------------|--------|
| Villacian 2004       | 8.50 (1.50, 48.20) | 2.19   |
| Drapeau 2007         | 1.11 (1.02, 1.22)  | 18.33  |
| Cenizal 2008         | 1.63 (0.54, 4.90)  | 4.62   |
| Cotton 2008          | 2.04 (0.80, 5.30)  | 5.10   |
| Shet 2009            | 1.20 (0.29, 5.28)  | 2.98   |
| Ramsay 2010          | 4.07 (2.20, 7.53)  | 9.60   |
| Crum–Clain 2011      | 3.10 (1.22, 7.67)  | 5.89   |
| Farley 2015          | 1.54 (1.22, 1.94)  | 16.48  |
| Lemma 2015           | 1.03 (0.22, 4.84)  | 2.68   |
| Gebremedhin 2016     | 4.56 (0.79, 26.23) | 2.15   |
| Viera 2016           | 0.28 (0.01, 5.32)  | 0.73   |
| Farley 2017          | 2.92 (1.05, 8.12)  | 5.16   |
| Alexander 2017       | 1.97 (0.98, 3.96)  | 8.42   |
| Reid 2017            | 1.36 (1.03, 1.79)  | 15.69  |
| Overall (I² = 68.3%, p = 0.000) | 1.80 (1.37, 2.36); P < 0.001 | 100.00 |

NOTE: Weights are from random effects analysis.

Figure 6. Association of previous antibiotic therapy with the risk of methicillin-resistant *Staphylococcus aureus* colonization in patients with human immunodeficiency virus infection. OR, odds ratio; CI, confidence interval.27–29,32,35–38,40,43,47,50–53,56

| Study                | OR (95% CI) | Weight |
|----------------------|-------------|--------|
| Turnboll 2002        | 2.89 (1.67, 5.02) | 12.82  |
| McDonald 2003        | 7.10 (0.99, 55.10) | 1.42   |
| Villacian 2004       | 10.01 (1.60, 62.00) | 1.78   |
| Cenizal 2008         | 4.34 (1.42, 13.19) | 4.39   |
| Shet 2009            | 2.25 (0.54, 5.42)  | 6.58   |
| Ramsay 2010          | 4.31 (2.37, 7.84)  | 11.52  |
| Giuliano 2010        | 0.98 (0.36, 2.69)  | 5.24   |
| Crum–Clain 2011      | 2.24 (1.14, 4.41)  | 9.74   |
| Kyaw 2012            | 5.30 (1.64, 17.09) | 4.02   |
| Everett 2014         | 3.50 (1.30, 9.30)  | 5.16   |
| Gebremedhin 2016     | 2.74 (0.54, 13.91) | 2.22   |
| Farley 2017          | 1.26 (0.49, 3.20)  | 5.88   |
| Alexander 2017       | 3.75 (1.74, 8.08)  | 8.00   |
| Reid 2017            | 1.79 (1.00, 3.20)  | 11.95  |
| Regina Pedrosa Soares 2018 | 1.49 (0.54, 4.17) | 5.10   |
| Hsu 2020             | 3.89 (1.22, 12.43) | 4.09   |
| Overall (I² = 19.9%, p = 0.231) | 2.69 (2.09, 3.43); P < 0.001 | 100.00 |

NOTE: Weights are from random effects analysis.
NOTE: Weights are from random effects analysis

Overall (I−squared = 39.7%, p = 0.057)

| Study ID | OR (95% CI) | Weight |
|----------|-------------|--------|
| Sissolak 2002 | 1.70 (0.50, 5.50) | 3.46 |
| Mathews 2005 | 2.40 (1.00, 5.60) | 5.89 |
| Drapeau 2007 | 4.17 (1.37, 12.50) | 3.98 |
| Padoveze 2008 | 1.42 (0.35, 5.79) | 2.63 |
| Ramsay 2010 | 2.03 (1.14, 3.63) | 9.96 |
| Crum−Cianflone 2011 | 1.65 (0.60, 4.50) | 4.62 |
| Siberry 2012 | 3.40 (1.10, 10.90) | 3.73 |
| Piyaw 2012 | 4.40 (1.53, 12.90) | 4.21 |
| Vyas 2014 | 3.04 (1.71, 5.41) | 10.04 |
| Farley 2015 | 1.36 (1.23, 1.51) | 22.46 |
| Gebremedhin 2016 | 1.42 (0.26, 7.92) | 1.84 |
| Viera 2016 | 0.75 (0.35, 1.75) | 6.51 |
| Alexander 2017 | 1.29 (0.53, 3.18) | 5.55 |
| Reid 2017 | 1.58 (1.01, 2.46) | 13.04 |
| Regina Pedrosa Soares 2018 | 1.18 (0.24, 5.75) | 2.10 |

Overall (I−squared = 39.7%, p = 0.057)

| Study ID | OR (95% CI) | Weight |
|----------|-------------|--------|
| Sissolak 2002 | 0.40 (0.10, 1.30) | |
| McDonald 2003 | 0.30 (0.08, 1.00) | |
| Villacian 2004 | 3.20 (0.40, 28.10) | |
| Cenizal 2008 | 1.25 (0.38, 4.17) | |
| Giuliani 2010 | 1.06 (0.41, 2.71) | |
| Crum−Cianflone 2011 | 2.01 (0.67, 6.03) | |
| Siberry 2012 | 0.91 (0.31, 2.50) | |
| Vyas 2014 | 0.71 (0.39, 1.30) | |
| Subtotal (I−squared = 20.1%, p = 0.270) | 0.86 (0.57, 1.32); P=0.495 |

Antiretroviral therapy

| Study ID | OR (95% CI) | Weight |
|----------|-------------|--------|
| McDonald 2003 | 0.20 (0.06, 0.71) | |
| Mathews 2005 | 0.80 (0.50, 1.50) | |
| Drapeau 2007 | 1.86 (0.65, 5.29) | |
| Padoveze 2008 | 0.50 (0.28, 0.89) | |
| Shet 2009 | 0.74 (0.33, 1.52) | |
| Farley 2015 | 0.85 (0.75, 0.96) | |
| Regina Pedrosa Soares 2018 | 0.35 (0.08, 1.45) | |
| Subtotal (I−squared = 49.6%, p = 0.064) | 0.71 (0.50, 0.99); P=0.041 |

NOTE: Weights are from random effects analysis

Figure 7. Association of CD4+ count with the risk of methicillin-resistant *Staphylococcus aureus* colonization in patients with human immunodeficiency virus infection. OR, odds ratio; CI, confidence interval.26,30,31,36,38–40,44,45,47,48,51–53

Figure 8. Association of highly active antiretroviral therapy (HAART) and antiretroviral therapy with the risk of methicillin-resistant *Staphylococcus aureus* colonization in patients with human immunodeficiency virus infection. OR, odds ratio; CI, confidence interval.26,28–33,35,37–39,44,45,53
infection severity in these patients, which could be attributed to ART and the current use of antibiotics. However, sex difference, HAART use, viral load and current TMP–SMX use did not affect the risk of MRSA colonization and infection in patients with HIV infection. These results could be explained by the number of included studies, adjusted factors, statistical power and the reliability of results reported by each study. Although most of the pooled conclusions were stable, male patients with HIV infection potentially had a lower prevalence of MRSA colonization and infection than female patients. This could be explained by the sex difference in the prevalence of MRSA colonization and infection among patients with HIV infection.

This current meta-analysis observed that the country affected the association of previous hospitalization and study design or reported outcomes affected that of previous hospitalization and CD4+ count with the risk of MRSA colonization and infection. In addition, previous hospitalization and CD4+ count did not affect the risk of MRSA colonization and infection for pooled studies conducted in Asia. Moreover, CD4+ count was not associated with the risk of MRSA colonization and infection in pooled case–control studies. This could be because the number of studies in these subgroups was smaller than expected, whereas the pooled 95% CI was broad and nonsignificant associations were observed. Finally, the definition of MRSA

Table 9. Association of Centers for Disease Control and Prevention (CDC) classification and viral load with the risk of methicillin-resistant Staphylococcus aureus colonization in patients with human immunodeficiency virus infection. OR, odds ratio; CI, confidence interval.26,27,30–32,34,37,44,48,49,53,54

| Study ID | CDC classification (C vs AB) | OR (95% CI) |
|----------|-----------------------------|-------------|
|          |                             |             |
| Sissolak 2002 |                             | 1.00 (0.30, 3.40) |
| Tumbarello 2002 |                             | 3.85 (1.47, 10.12) |
| Cotton 2008 |                             | 3.70 (1.40, 12.90) |
| Giuliani 2010 |                             | 1.39 (0.12, 9.32) |
| Vyas 2014 |                             | 3.11 (1.68, 5.76) |
| Olalekan 2016 |                             | 2.10 (0.80, 5.20) |
| Subtotal (I−squared = 0.0%, p = 0.516) |                             | 2.66 (1.80, 3.93); P<0.001 |
|          |                             |             |
| Sissolak 2002 |                             | 1.10 (0.40, 3.60) |
| Mathews 2005 |                             | 4.51 (2.72, 7.48) |
| Drapeau 2007 |                             | 1.45 (0.52, 4.00) |
| Cenizal 2008 |                             | 1.06 (0.36, 3.09) |
| Vieira 2016 |                             | 1.10 (0.47, 2.57) |
| Regina Pedrosa Soares 2018 |                             | 1.77 (0.62, 5.06) |
| Hirota 2020 |                             | 1.30 (0.48, 3.30) |
| Subtotal (I−squared = 61.1%, p = 0.017) |                             | 1.64 (0.95, 2.83); P=0.075 |

NOTE: Weights are from random effects analysis.
colonization and infection varies, which could affect the potential risk factors (Table 2).

This current meta-analysis had the following limitations: (i) the included studies had cohort, case-control and cross-sectional designs; causality could not constructed, and uncontrolled selection, recall or other biases were not assessed; (ii) most studies reported the results of crude data and these results were not adjusted with potential covariates, which could affect the risk of MRSA colonization and infection; (iii) the heterogeneity for several factors were not fully explained by sensitivity and subgroup analyses; (iv) the study was not registered in PROSPERO and the transparency of the current study was restricted; and (v) the inherent limitations of traditional meta-analysis based on published articles, including publication bias, and the analysis based on pooled data prevented the performance of more detailed stratified analyses.

Figure 10. Association of current antibiotic use, skin lesions, intravenous device use, current trimethoprim–sulfamethoxazole (TMP–SMX) use and a history of methicillin-resistant Staphylococcus aureus (MRSA) colonization with the risk of MRSA colonization in patients with human immunodeficiency virus infection. OR, odds ratio; CI, confidence interval.26–29,32–35,37,38,40,47,48,51,55

| Study ID | OR (95% CI) |
|----------|-------------|
| Sissolak 2002 | 0.20 (0.06, 0.80) |
| Cenizal 2008 | 0.03 (0.00, 0.41) |
| Padoveze 2008 | 0.12 (0.05, 0.58) |
| Subtotal (I² = 0.0%, p = 0.399) | 0.13 (0.05, 0.32); P < 0.001 |
| Skin lesions | | |
| Sissolak 2002 | 1.30 (0.40, 4.40) |
| Villacian 2004 | 0.90 (0.10, 16.10) |
| Shet 2009 | 2.00 (0.55, 5.32) |
| Popovich 2020 | 2.70 (1.20, 6.10) |
| Subtotal (I² = 0.0%, p = 0.706) | 2.02 (1.15, 3.55); P = 0.015 |
| Intravenous device | | |
| Sissolak 2002 | 8.60 (0.90, 81.30) |
| Tumbarello 2002 | 3.39 (1.45, 7.94) |
| Villacian 2004 | 3.20 (0.20, 65.30) |
| Popovich 2020 | 2.00 (1.00, 3.70) |
| Subtotal (I² = 0.0%, p = 0.553) | 2.61 (1.59, 4.29); P < 0.001 |
| Current TMP–SMX use | | |
| Tumbarello 2002 | 0.76 (0.36, 1.60) |
| McDonald 2003 | 4.60 (1.00, 21.50) |
| Villacian 2004 | 19.30 (1.10, 347.40) |
| Cotton 2008 | 1.03 (0.48, 2.38) |
| Giuliani 2010 | 0.20 (0.01, 3.63) |
| Crum–Cianflone 2011 | 1.16 (0.26, 5.12) |
| Gebremedhin 2016 | 3.79 (0.68, 21.10) |
| Vieira 2016 | 1.70 (0.60, 4.80) |
| Subtotal (I² = 39.7%, p = 0.114) | 1.48 (0.81, 2.69); P = 0.203 |
| History of MRSA colonization | | |
| McDonald 2003 | 20.00 (10.20, 39.60) |
| Cenizal 2008 | 9.71 (2.19, 43.04) |
| Shet 2009 | 1.61 (0.62, 4.27) |
| Crum–Cianflone 2011 | 6.62 (2.20, 26.20) |
| Kyaw 2012 | 6.00 (1.14, 31.89) |
| Alexander 2017 | 3.00 (0.18, 48.89) |
| Subtotal (I² = 72.9%, p = 0.002) | 6.30 (2.50, 15.90); P < 0.001 |

NOTE: Weights are from random effects analysis.
In conclusion, the findings of this current meta-analysis provide a comprehensive list of risk factors for MRSA colonization and infection in patients with HIV infection. These risk factors include previous hospitalization, previous antibiotic therapy, CD4+ count, CDC classification of stage C, skin lesions, intravenous device use and an MRSA colonization history. The potential protective factors were ART and the current use of antibiotics. The results of this current meta-analysis should be verified by further large-scale prospective studies.

Declaration of conflicting interest
The authors declare that there are no conflicts of interest.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: This work was supported by the Department of Science and Technology of Jiangxi Province (grant no. 2015BBG70226).

ORCID iD
Wei Zhang https://orcid.org/0000-0002-3716-1831

References
1. Smith PW, Bennett G, Bradley S, et al. SHEA/APIC Guideline: Infection prevention and control in the long-term care facility. Am J Infect Control 2008; 36: 504–535.
2. Gordon RJ and Lowy FD. Pathogenesis of meticillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46: S350–S359.
3. Thomer L, Schneewind O and Missiakas D. Pathogenesis of Staphylococcus aureus Bloodstream Infections. Annu Rev Pathol 2016; 11: 343–364.
4. Zetola N, Francis JS, Nuermberger EL, et al. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005; 5: 275–286.
5. Bal AM, Coombs GW, Holden MTG, et al. Genomic insights into the emergence and spread of international clones of healthcare-, community- and livestock-associated meticillin-resistant Staphylococcus aureus: Blurring of the traditional definitions. J Glob Antimicrob Resist 2016; 6: 95–101.
6. Chacko J, Kuruvila M and Bhat GK. Factors affecting the nasal carriage of meticillin-resistant Staphylococcus aureus in human immunodeficiency virus-infected patients. Indian J Med Microbiol 2009; 27: 146–148.
7. Madhivanan P, Mothi SN, Kumarasamy N, et al. Clinical manifestations of HIV infected children. Indian J Pediatr 2003; 70: 615–620.
8. Befus MB, Miko BA, Herzig CT, et al. HIV and colonization with Staphylococcus aureus in two maximum-security prisons in New York State. J Infect 2016; 73: 568–577.
9. Santosaningsih D, Santoso S, Verbrugh HA, et al. Risk Factors for Methicillin-Resistant Staphylococcus aureus Carriage among Patients at Admission to the Surgical Ward in a Resource-Limited Hospital in Indonesia. Am J Trop Med Hyg 2017; 97: 1310–1312.
10. Mohd-Zain Z, Mohd-Nawi SFA, Adnan A, et al. Frequency and molecular epidemiology of Panton-Valentine leukocidin gene in Staphylococcus aureus colonising HIV-infected patients. Malays J Pathol 2017; 39: 115–122.
11. Wu CJ, Ko WC, Ho MW, et al. Prevalence of and risk factors for meticillin-resistant Staphylococcus aureus colonization among human immunodeficient virus-infected out patients in Taiwan: oral Candida colonization as a comparator. J Oral Microbiol 2017; 9: 1322446.
12. Kotpal R, S KP, Bhalla P, et al. Incidence and Risk Factors of Nasal Carriage of Staphylococcus aureus in HIV-Infected Individuals in Comparison to HIV-Uninfected Individuals: A Case-Control Study. J Int Assoc Provid AIDS Care 2016; 15: 141–147.
13. Neupane K, Rayamajhee B, Acharya J, et al. Comparison of Nasal Colonization of Meticillin-Resistant Staphylococcus aureus in HIV-Infected and Non-HIV...
Patients Attending the National Public Health Laboratory of Central Nepal. *Can J Infect Dis Med Microbiol* 2018; 2018: 4508757.

14. McKinnell JA, Miller LG, Eells SJ, et al. A systematic literature review and meta-analysis of factors associated with methicillin-resistant Staphylococcus aureus colonization at time of hospital or intensive care unit admission. *Infect Control Hosp Epidemiol* 2013; 34: 1077–1086.

15. de Carvalho Ferreira D, da Silva GR, Cavalcante FS, et al. Methicillin-resistant Staphylococcus aureus in HIV patients: risk factors associated with colonization and/or infection and methods for characterization of isolates – a systematic review. *Clinics (Sao Paulo)* 2014; 69: 770–776.

16. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010; 8: 336–341.

17. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (2009).

18. DerSimonian R and Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7: 177–188.

19. Ades AE, Lu G and Higgins JP. The interpretation of random-effects meta-analysis in decision models. *Med Decis Making* 2005; 25: 646–654.

20. Deeks JJ, Fellow JPHSSV and Altman DG. Analyzing data and undertaking meta-analyses. In: Higgins J and Green S (eds) *Cochrane Handbook for Systematic Reviews of Interventions* 501. Oxford, UK, 2008.

21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557–560.

22. Tobias A. Assessing the influence of a single study in meta-analysis. *Stata Technical Bulletin* 1999; 47: 15–17.

23. Altman DG and Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003; 326: 219.

24. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; 315: 629–634.

25. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994; 50: 1088–1101.

26. Sissolak D, Geusu A, Heinze G, et al. Risk factors for nasal carriage of Staphylococcus aureus in infectious disease patients, including patients infected with HIV, and molecular typing of colonizing strains. *Eur J Clin Microbiol Infect Dis* 2002; 21: 88–96.

27. Tumbarello M, de Gaetano Donati K, Tacconelli E, et al. Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in HIV-infected patients. *J Antimicrob Chemother* 2002; 50: 375–382.

28. McDonald LC, Lauderdale TL, Lo HJ, et al. Colonization of HIV-infected outpatients in Taiwan with methicillin-resistant and methicillin-susceptible Staphylococcus aureus. *Int J STD AIDS* 2003; 14: 473–477.

29. Villacian JS, Barkham T, Earnest A, et al. Prevalence of and risk factors for nasal colonization with Staphylococcus aureus among human immunodeficiency virus-positive outpatients in Singapore. *Infect Control Hosp Epidemiol* 2004; 25: 438–440.

30. Mathews WC, Caperna JC, Barber RE, et al. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. *J Acquir Immune Defic Syndr* 2005; 40: 155–160.

31. Drapeau CM, Angeletti C, Festa A, et al. Role of previous hospitalization in clinically-significant MRSA infection among HIV-infected inpatients: results of a case-control study. *BMC Infect Dis* 2007; 7: 36.

32. Cenizal MJ, Hardy RD, Anderson M, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. *J Acquir Immune Defic Syndr* 2008; 48: 567–571.

33. Padoveze MC, de Jesus Pedro R, Blum-Menezes D, et al. Staphylococcus aureus nasal colonization in HIV outpatients: persistent or transient? *Am J Infect Control* 2008; 36: 187–191.
34. Cotton MF, Wasserman E, Smit J, et al. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. *BMC Infect Dis* 2008; 8: 40.

35. Shet A, Mathema B, Mediavilla JR, et al. Colonization and subsequent skin and soft tissue infection due to methicillin-resistant Staphylococcus aureus in a cohort of otherwise healthy adults infected with HIV type 1. *J Infect Dis* 2009; 200: 88–93.

36. Ramsetty SK, Stuart LL, Blake RT, et al. Risks for methicillin-resistant Staphylococcus aureus colonization or infection among patients with HIV infection. *HIV Med* 2010; 11: 389–394.

37. Giuliani M, Longo B, Latini A, et al. No evidence of colonization with community-acquired methicillin-resistant Staphylococcus aureus in HIV-1-infected men who have sex with men. *Epidemiol Infect* 2010; 138: 738–742.

38. Crum-Cianflone NF, Shadyab AH, Weintrob A, et al. Association of methicillin-resistant Staphylococcus aureus (MRSA) colonization with high-risk sexual behaviors in persons infected with human immunodeficiency virus (HIV). *Medicine (Baltimore)* 2011; 90: 379–389.

39. Siberry GK, Frederick T, Emmanuel P, et al. Methicillin-Resistant Staphylococcus aureus Infections in Human Immunodeficiency Virus-Infected Children and Adolescents. *AIDS Res Treat* 2012; 2012: 627974.

40. Kyaw WM, Lee LK, Siong WC, et al. Prevalence of and risk factors for MRSA colonization in HIV-positive outpatients in Singapore. *AIDS Res Ther* 2012; 9: 33.

41. Popovich KJ, Hota B, Aroutcheva A, et al. Community-associated methicillin-resistant Staphylococcus aureus colonization burden in HIV-infected patients. *Clin Infect Dis* 2013; 56: 1067–1074.

42. Oliva A, Lichtner M, Mascelino MT, et al. Study of methicillin-resistant Staphylococcus aureus (MRSA) carriage in a population of HIV-negative migrants and HIV-infected patients attending an outpatient clinic in Rome. *Ann Ig* 2013; 25: 99–107.

43. Everett CK, Subramanian A, Jarisberg LG, et al. Characteristics of Drug-Susceptible and Drug-Resistant Staphylococcus aureus Pneumonia in Patients with HIV. *Epidemiology (Sunnyvale)* 2013; 3: 122.

44. Vyas KJ, Shadyab AH, Lin CD, et al. Trends and factors associated with initial and recurrent methicillin-resistant Staphylococcus aureus (MRSA) skin and soft-tissue infections among HIV-infected persons: an 18-year study. *J Int Assoc Provid AIDS Care* 2014; 13: 206–213.

45. Farley JE, Hayat MJ, Sacamano PL, et al. Prevalence and risk factors for methicillin-resistant Staphylococcus aureus in an HIV-positive cohort. *Am J Infect Control* 2015; 43: 329–335.

46. Lemma MT, Zenebe Y, Tulu B, et al. Methicillin Resistant Staphylococcus aureus among HIV Infected Pediatric Patients in Northwest Ethiopia: Carriage Rates and Antibiotic Co-Resistance Profiles. *PLoS One* 2015; 10: e0137254.

47. Gebremedhin G, Gebremariam TT, Wasihun AG, et al. Prevalence and risk factors of methicillin-resistant Staphylococcus aureus colonization among HIV patients in Mekelle, Northern Ethiopia. *Springerplus* 2016; 5: 877.

48. Vieira MT, Marlow MA, Aguiar-Alves F, et al. Living Conditions as a Driving Factor in Persistent Methicillin-resistant Staphylococcus aureus Colonization Among HIV-infected Youth. *Pediatr Infect Dis J* 2016; 35: 1126–1131.

49. Olalekan AO, Taiwo SS, Smith SI, et al. Persistent Staphylococcus aureus nasal colonization in ambulatory human immunodeficiency virus-infected patients in Nigeria: Risk factors and molecular features. *J Microbiol Immunol Infect* 2016; 49: 992–995.

50. Farley JE, Starbird LE, Anderson J, et al. Methodologic considerations of household-level methicillin-resistant Staphylococcus aureus decolonization among persons living with HIV. *Am J Infect Control* 2017; 45: 1074–1080.
51. Alexander A, Vishwanath S, Sellvaraj A, et al. Methicillin-resistant Staphylococcus aureus nasal colonization in human immunodeficiency virus-infected patients. *Annals of Tropical Medicine and Public Health* 2017; 10: 1809.

52. Reid MJA, Steenhoff AP, Mannathoko N, et al. Staphylococcus aureus nasal colonization among HIV-infected adults in Botswana: prevalence and risk factors. *AIDS Care* 2017; 29: 961–965.

53. Regina Pedrosa Soares C, de Lira CR, Cunha MAH, et al. Prevalence of nasal colonization by methicillin-resistant Staphylococcus aureus in outpatients living with HIV/AIDS in a Referential Hospital of the Northeast of Brazil. *BMC Res Notes* 2018; 11: 794.

54. Hirota K, Watanabe D, Koizumi Y, et al. Observational study of skin and soft-tissue Staphylococcus aureus infection in patients infected with HIV-1 and epidemics of Panton-Valentine leucocidin-positive community-acquired MRSA infection in Osaka, Japan. *J Infect Chemother* 2020; 26: 1254–1259.

55. Popovich KJ, Snitkin ES, Zawitz C, et al. Frequent Methicillin-Resistant Staphylococcus aureus Introductions Into an Inner-city Jail: Indications of Community Transmission Networks. *Clin Infect Dis* 2020; 71: 323–331.

56. Hsu YY, Wu D, Hung CC, et al. Methicillin-resistant Staphylococcus aureus nasal colonization among HIV-infected patients in Taiwan: prevalence, molecular characteristics and associated factors with nasal carriage. *BMC Infect Dis* 2020; 20: 254.

57. Duval S and Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000; 56: 455–463.

58. Zervou FN, Zacharioudakis IM, Ziakas PD, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV infection: a meta-analysis. *Clin Infect Dis* 2014; 59: 1302–1311.

59. Sabbagh P, Riahi SM, Gamble HR, et al. The global and regional prevalence, burden, and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV-infected people: A systematic review and meta-analysis. *Am J Infect Control* 2019; 47: 323–333.

60. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. *J Clin Invest* 2003; 111: 1265–1273.

61. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. *Am J Infect Control* 2006; 34: S3–S10; discussion S64-73.

62. Tuazon CU and Sheagren JN. Increased rate of carriage of Staphylococcus aureus among narcotic addicts. *J Infect Dis* 1974; 129: 725–727.

63. Davis KA, Stewart JJ, Crouch HK, et al. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. *Clin Infect Dis* 2004; 39: 776–782.

64. Huang SS and Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. *Clin Infect Dis* 2003; 36: 281–285.